Phase I clinical and pharmacokinetics study of high-dose toremifene in postmenopausal patients with advanced breast cancer
- 1 January 1992
- journal article
- clinical trial
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 30 (3) , 174-178
- https://doi.org/10.1007/bf00686307
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- High dose toremifene (240 mg daily) is effective as first line hormonal treatment in advanced breast cancer an ongoing phase II multicenter Finnish-Latvian cooperative studyBreast Cancer Research and Treatment, 1990
- Phase II trials with toremifene in advanced breast cancer: A reviewBreast Cancer Research and Treatment, 1990
- A phase I study of toremifeneBreast Cancer Research and Treatment, 1990
- Phase I study of the tolerance and pharmacokinetics of toremifene in patients with cancerBreast Cancer Research and Treatment, 1990
- Pharmacokinetics of toremifeneJournal of Steroid Biochemistry, 1990
- Antitumor actions of toremifene in the 7,12-dimethylbenzanthracene (DMBA)-induced rat mammary tumor modelEuropean Journal of Cancer and Clinical Oncology, 1988
- Toremifene, a new antiestrogenic compound, for treatment of advanced breast cancer. Phase II studyEuropean Journal of Cancer and Clinical Oncology, 1988
- ALTERNATIVE MECHANISM OF ACTION OF "ANTI-OESTROGENS" IN BREAST CANCERThe Lancet, 1987
- Estrogens and antiestrogens stimulate release of bone resorbing activity by cultured human breast cancer cells.Journal of Clinical Investigation, 1985
- SAFETY OF TAMOXIFENThe Lancet, 1978